Last reviewed: July 2, 2026
Last updated: July 2, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Wegovy (semaglutide) became available to patients in June 2021, marking a major milestone in weight loss medicine after decades of limited pharmaceutical options. The approval was based on the STEP clinical trials, which showed participants lost an average of 15% of body weight over 68 weeks. PlexusDx provides access to compounded semaglutide injection therapy through licensed 503A pharmacies, delivering the same active ingredient at a fraction of brand-name costs.
When Did Wegovy Enter the Market?
Novo Nordisk received FDA approval for Wegovy on June 4, 2021, making it the first GLP-1 receptor agonist approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. Prior to this approval, semaglutide had been used off-label for weight loss, but Wegovy represented the first official regulatory pathway. The approval came after successful completion of the STEP program, a four-trial research initiative involving over 4,500 participants.
Before Wegovy's arrival, weight loss medication options were extremely limited. Phentermine and a few combination therapies existed, but they showed modest results and came with significant safety concerns. The introduction of Wegovy changed the landscape by offering a mechanism of action—GLP-1 signaling—that targets multiple biological pathways involved in appetite regulation and metabolism. This scientific breakthrough made Wegovy one of the most significant pharmaceutical launches in metabolic health within the past 20 years.
Semaglutide's Clinical Development and Approval Timeline
Semaglutide was originally developed as a diabetes treatment and approved by the FDA in 2017 under the brand name Ozempic. Researchers and clinicians noticed that patients taking semaglutide for Type 2 diabetes experienced significant weight loss as a secondary benefit. This observation sparked the development of a dedicated weight loss formulation, leading to the STEP trials that specifically measured efficacy and safety in non-diabetic and diabetic individuals seeking weight management. The clinical data proved compelling enough to warrant fast-track FDA review status.
The STEP trials demonstrated that semaglutide produced weight loss in a dose-dependent manner, with participants on the 2.4 mg weekly dose experiencing average weight reductions of 15% at 68 weeks compared to 2.7% in the placebo group. Safety monitoring showed gastrointestinal side effects—primarily nausea, vomiting, and diarrhea—were the most common adverse events, though they typically improved over time. By the time Wegovy launched in June 2021, the medical community had strong real-world evidence supporting its use in both diabetic and non-diabetic populations.
Why Compounded Semaglutide Offers a Better Alternative
Since Wegovy's launch over three years ago, brand-name pricing has climbed to $1,300 per month or higher without insurance, placing the medication out of reach for millions of Americans. Compounded semaglutide from licensed 503A pharmacies delivers the identical active pharmaceutical ingredient at a substantially lower cost. PlexusDx provides compounded semaglutide injections starting at $149 per month—a transparent, flat-rate pricing model where your dose may increase but your monthly cost remains the same.
Compounded medications are prepared by licensed pharmacists using FDA-grade materials and quality standards identical to brand-name formulations. PlexusDx sources all semaglutide from accredited 503A compounding pharmacies, never from 503B bulk manufacturers, ensuring pharmaceutical-grade purity and consistency. Because compounded therapy eliminates brand-name markup and advertising costs, patients access the same efficacious treatment without the financial barrier that makes Wegovy unaffordable for most.
Personalization Through Genetic Testing and Peptide Science
The original Wegovy trials used a one-size-fits-all dosing protocol, but modern precision medicine recognizes that individuals respond differently to GLP-1 therapy based on their genetic makeup. PlexusDx offers the Precision Peptide Genetic Test—a peptide-pathway genetic analysis that examines 14 molecular pathways, 49 key peptides, and 150+ genetic insights related to weight regulation and metabolic response. This test identifies variants in genes like GIPR, GLP1R, FTO, and MC4R that influence how your body responds to semaglutide and other peptide therapies.
Understanding your genetic predispositions allows PlexusDx to recommend the most effective compound formulation—whether semaglutide, tirzepatide (a newer dual GLP-1/GIP agonist), or even the GLP-Squared protocol combining both compounds. The Precision Peptide Genetic Test costs $99 as an add-on after your first month of treatment, helping you avoid trial-and-error dosing and accelerate your results. This level of personalization was simply not available when Wegovy first launched in 2021.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How long has Wegovy actually been on the market?
Wegovy received FDA approval on June 4, 2021, making it available to patients for over three years. Since its launch, it has become the most recognized brand-name GLP-1 weight loss medication, though supply shortages and high pricing have limited access for many patients seeking this evidence-based treatment.
Is Wegovy still the only semaglutide option for weight loss?
While Wegovy is the only FDA-approved brand-name semaglutide for weight management, compounded semaglutide from licensed 503A pharmacies is a clinically equivalent alternative. PlexusDx provides compounded semaglutide injections starting at $149/month, delivering the same active ingredient without brand-name pricing.
What clinical evidence supports semaglutide for weight loss?
The STEP clinical trials, which led to Wegovy's approval, involved over 4,500 participants and showed average weight loss of 15% over 68 weeks at the 2.4 mg dose compared to 2.7% with placebo. Multiple post-launch real-world studies have confirmed these results, making semaglutide one of the most effective weight loss medications available.
Why is compounded semaglutide so much cheaper than Wegovy?
Compounded semaglutide eliminates brand-name markup, advertising costs, and corporate overhead that make Wegovy cost $1,300+ monthly. PlexusDx sources from licensed 503A compounding pharmacies using FDA-grade materials at the same pharmaceutical standard, passing savings directly to patients through transparent flat-rate pricing starting at $149/month.
Can genetic testing help me respond better to semaglutide?
Yes—PlexusDx Precision Peptide Genetic Test identifies variants in GIPR, GLP1R, FTO, and MC4R genes that influence your metabolic response to GLP-1 therapy. This $99 add-on test maps 14 pathways and 150+ insights, helping PlexusDx recommend whether semaglutide, tirzepatide, or a dual-compound protocol will work best for your unique biology.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What is the Maximum Dose of Ozempic for Weight Loss?
Is Wegovy Covered by Insurance for Weight Loss? A Comprehensive Guide